This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Malignant fibrous histiocytoma

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Malignant fibrous histiocytomas are tumours arising from primitive mesenchymal cells which occur predominantly in soft tissues, most often in relation to skeletal muscle. Like benign fibrous histiocytomas, they are composed of a mixture of cells resembling myofibroblasts, fibroblasts, histiocytes, primitive mesenchymal cells, and cells having intermediate or mixed features.

  • malignant fibrous histiocytomas account for 20-30% of soft tissue sarcomas
  • they affect all age groups, with a peak incidence in the seventh decade. The incidence is slightly higher in males
  • sites of origin of malignant fibrous histiocytomas
    • lower extremities (approx. 50%)
    • upper extremeties (approx. 20%)
    • abdominal cavity including retroperitoneum (approx. 20%)
  • majority arise in relation to skeletal muscle; occasionally they involve the deep fascia or less often the subcutaneous tissue; the osseous tumours occur more commonly around the knee

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.